KNSA Kiniksa Pharmaceuticals Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: KNSA

Price (delayed)

$76.08

Market cap

$5.94B

P/E Ratio

71.1

Dividend/share

N/A

EPS

$1.07

Enterprise value

$5.77B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 95
Highlights
KNSA's gross profit has surged by 66% year-on-year and by 12% since the previous quarter
Kiniksa Pharmaceuticals's revenue has surged by 59% YoY and by 12% QoQ
The P/E is 22% above the last 4 quarters average of 59.9
Sector: Healthcare
Industry: Biotechnology
Website: http://www.kiniksa.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of KNSA

KNSA stock price

How has the Kiniksa Pharmaceuticals stock price performed over time
Intraday
-2.46%
1 week
-1.98%
1 month
-3.73%
1 year
109.41%
YTD
84.44%
QTD
18.97%

Financial performance

How have Kiniksa Pharmaceuticals's revenue and profit performed over time
Revenue
$840.85M
Gross profit
$755.28M
Operating income
$100.25M
Net income
$80.66M
Gross margin
89.8%
Net margin
9.6%
KNSA's gross profit has surged by 66% year-on-year and by 12% since the previous quarter
Kiniksa Pharmaceuticals's revenue has surged by 59% YoY and by 12% QoQ
KNSA's net income is up by 10% since the previous quarter
KNSA's operating income is up by 8% since the previous quarter

Price vs fundamentals

How does KNSA's price correlate with its fundamentals

Growth

What is Kiniksa Pharmaceuticals's growth rate over time

Valuation

What is Kiniksa Pharmaceuticals stock price valuation
KNSA P/E details
P/E
71.1
P/B
8.95
P/S
7.02
EV/EBIT
50.5
EV/EBITDA
48.1
EV/Sales
6.86
The P/E is 22% above the last 4 quarters average of 59.9
The EPS is up by 9% since the previous quarter
KNSA's price to book (P/B) is 135% higher than its 5-year quarterly average of 3.9 and 50% higher than its last 4 quarters average of 6.1
Kiniksa Pharmaceuticals's equity has increased by 32% YoY and by 8% from the previous quarter
Kiniksa Pharmaceuticals's revenue has surged by 59% YoY and by 12% QoQ
The stock's price to sales (P/S) is 44% more than its last 4 quarters average of 5.0 but 2.7% less than its 5-year quarterly average of 7.4

Efficiency

How efficient is Kiniksa Pharmaceuticals business performance
The return on sales has declined by 3.5% since the previous quarter
KNSA's ROIC is down by 3.6% from the previous quarter
Kiniksa Pharmaceuticals's return on equity has increased by 3% QoQ
Kiniksa Pharmaceuticals's return on assets has increased by 2% QoQ

Dividends

What is KNSA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KNSA.

Financial health

How did Kiniksa Pharmaceuticals financials performed over time
KNSA's total liabilities is up by 46% year-on-year and by 10% since the previous quarter
The company's total assets rose by 36% YoY and by 9% QoQ
The debt is 99% smaller than the equity
The debt to equity has plunged by 50% YoY
Kiniksa Pharmaceuticals's equity has increased by 32% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.